By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


Company News
Ablynx (ABLYF) Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP, A Rare Blood Clotting Disorder 9/29/2015 9:01:25 AM
Ablynx (ABLYF) Announces Half-Year Results For 2015 8/27/2015 9:15:23 AM
Ablynx (ABLYF) Significantly Expands Its Immuno-Oncology Collaboration With Merck & Co. (MRK) 7/22/2015 2:17:55 PM
Ablynx (ABLYF) Announces Extension Of Ion Channel Research Collaboration With Merck & Co. (MRK) 3/26/2015 10:39:44 AM
Ablynx (ABLYF) Initiates The First Of Two Phase IIb Ra Studies With Its Anti-Il-6R Nanobody, Partnered With AbbVie (ABBV) 3/17/2015 7:19:27 AM
Ablynx (ABLYF) Announces Warrant Exercise 3/16/2015 8:02:56 AM
Polar Capital Funds Plc And Fmr Llc Provide Notification Of Shareholding In Ablynx (ABLYF) 3/16/2015 7:28:20 AM
Aviva Plc And Aviva Investors Global Services Limited Provide Notification Of A 5.02% Shareholding In Ablynx (ABLYF) 3/3/2015 8:49:16 AM
Ablynx (ABLYF) Announces 2014 Full Year Results 2/26/2015 1:18:46 PM
Ablynx (ABLYF) Will Announce Its Full Year Results 2014 With Webcast 2/19/2015 8:30:10 AM